Given the rapid clinical improvement following anakinra, it was not necessary to escalate to other therapeutic strategies used in refractory cases of HLH, such as emapalumab (a monoclonal antibody targeting IFN-γ) or JAK inhibitors (16). Here, IFNG is linked to hemophagocytic syndrome.